Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm, MET+ NSCLC
NCT05261399Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Aug 2022; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05261399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261399.